How AI is applied across API Evangelist and APIs.io. Read my AI disclosure →
API Evangelist API Evangelist
Discovery
Learnings
Guidance
Toolbox
Alignment
API Evangelist LLC

Alzheon Highlights ORION-E4 Phase 3 Trial Launch for Oral Valiltramiprosate/ALZ-801 and Expansion of Its Oral Anti-Amyloid Aggregation Inhibitor Portfolio at CTAD 2026 Conference in Boston, November 16–19

calendar_today November 10, 2026 person alzheon domain alzheon
ORION-E4, the Second Phase 3 Trial of Oral Valiltramiprosate, Aims to Confirm Clinical Benefits Observed in the APOLLOE4 MCI Subgroup in APOE4/4 Patients with Mild Cognitive Impairment The post Alzheon Highlights ORION-E4 Phase 3 Trial Launch for Oral Valiltramiprosate/ALZ-801 and Expansion of Its Oral Anti-Amyloid Aggregation Inhibitor Portfolio at CTAD 2026 Conference in Boston, November 16–19 appeared first on Alzheon Preserving Future Memories .
open_in_new Read original post